Sugi Predict

Sugi Predict / Compounds / SCHEMBL20203438

SCHEMBL20203438

SCHEMBL20203438

CSc1ncc2cc(COC(=O)c3ccccc3)nc(N3CCCCC3)c2n1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.48
▸ KMT2A Q03164 2/20 0.48
▸ TP53 P04637 3/20 0.40
▸ LMNA P02545 2/20 0.40
▸ MAPT P10636 2/20 0.38
▸ ALOX5 P09917 1/20 0.37
▸ ALDH1A1 P00352 4/20 0.37
▸ TSHR P16473 1/20 0.37
▸ HPGD P15428 2/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.36
▸ POLB P06746 2/20 0.36
▸ TDP1 Q9NUW8 2/20 0.36
▸ NPY5R Q15761 1/20 0.36
▸ L3MBTL1 Q9Y468 2/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ P2RY12 Q9H244 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21403165 0.91 PDE4B (0.42) MEN1KMT2ATP53MAPTALDH1A1
SCHEMBL20203462 0.91 MEN1 (0.46) MEN1KMT2ATP53LMNAALDH1A1
SCHEMBL20203486 0.86 TP53 (0.40) TP53LMNAMAPTALOX5ALDH1A1
SCHEMBL31164152 0.82 KMT2A (0.42) MEN1KMT2ATP53LMNAMAPT
SCHEMBL18291265 0.82 KMT2A (0.42) MEN1KMT2ATP53LMNAMAPT
SCHEMBL20037634 0.82 TDP1 (0.43) MEN1KMT2ATP53LMNAMAPT
SCHEMBL20203513 0.80 KMT2A (0.42) MEN1KMT2ATP53LMNAALDH1A1
SCHEMBL20203540 0.80 KMT2A (0.42) MEN1KMT2ATP53LMNAALDH1A1
SCHEMBL23733423 0.80 TP53 (0.45) TP53LMNAMAPTALOX5ALDH1A1
SCHEMBL20203385 0.78 MEN1 (0.46) MEN1KMT2ALMNAMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11084814-B2 Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof TEIJIN PHARMA LIMITED (JP) 2021-08-10 — — US disclosed
US-11084814-B2 Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof TEIJIN PHARMA LIMITED (JP) 2021-08-10 — — US disclosed
EP-3546458-B1 ((PYRIDIN-2-YL)-AMINO)PYRIDO[3,4-D]PYRIMIDINE AND ((PYRIDAZIN-3-YL)-AMINO)PYRIDO[3,4-D]PYRIMIDINE DERIVATIVES AS CDK4/6 INHIBITORS FOR TREATING E.G. RHEUMATOID ARTHRITIS, ARTERIOSCLEROSIS, PULMONARY FIBROSIS, CEREBRAL INFARCTION OR CANCER TEIJIN PHARMA LTD (JP) 2021-01-06 — — EP disclosed
EP-3546458-A1 PYRIDO[3, 4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Teijin Pharma Limited (JP) 2019-10-02 — — EP disclosed
WO-2018097297-A1 PYRIDO[3, 4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF 帝人ファーマ株式会社 2018-05-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11084814-B2 Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof CDK4, CDK6, CDK16 MEN1 2438/4885KMT2A 657/4885TP53 176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.